FDA Grants EUA To Baricitinib-Remdesivir Combo For COVID-19

FDA on Thursday (Nov. 19) granted emergency authorization to Eli Lilly’s anti-inflammatory drug baricitinib to be used in combination with Gilead’s antiviral remdesivir for treatment of COVID-19 in hospitalized adult and pediatric patients who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. The EUA for baricitinib is the first emergency authorization of a drug that acts on the inflammation pathway, Patrizia Cavazzoni, acting director of FDA’s drug center, said in a press statement. “Despite advances in the management of...